

Ken Sato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3929143/publications.pdf>

Version: 2024-02-01

32
papers

777
citations

687363
13
h-index

501196
28
g-index

33
all docs

33
docs citations

33
times ranked

941
citing authors

#	ARTICLE	IF	CITATIONS
1	Adolescents with chronic hepatitis C might be good candidates for direct-acting antiviral therapy. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05690.	0.5	1
2	Real-world efficacy and safety of 12-week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. <i>Hepatology Research</i> , 2021, 51, 51-61.	3.4	20
3	Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C. <i>Biomedicines</i> , 2021, 9, 660.	3.2	2
4	Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately. <i>Internal Medicine</i> , 2021, 60, 3061-3070.	0.7	1
5	Successful treatment of Japanese hemophilia patient co-infected with HIV and HCV genotype 4a by glecaprevir/pibrentasvir therapy. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1725-1732.	0.8	2
6	Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19. <i>World Journal of Gastroenterology</i> , 2021, 27, 8370-8373.	3.3	2
7	Favorable outcome of retreatment by direct-acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure. <i>Hepatology Research</i> , 2020, 50, 303-312.	3.4	5
8	Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study. <i>Hepatology Research</i> , 2020, 50, 382-395.	3.4	28
9	Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment. <i>Cancers</i> , 2020, 12, 2906.	3.7	17
10	Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling. <i>World Journal of Hepatology</i> , 2020, 12, 350-362.	2.0	8
11	Characteristics of cases of hepatitis E in 2019 in Gunma prefecture: a small epidemic caused by the same subgenotype 3a strain. <i>Acta Hepatologica Japonica</i> , 2020, 61, 478-481.	0.1	1
12	Successful prolonged treatment of glecaprevir/pibrentasvir for chronic hepatitis C patient with treatment failure after 8-week therapy: a case report. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 592-597.	0.8	3
13	Sofosbuvir/Ribavirin therapy for patients experiencing failure of ombitasvir/paritaprevir/ritonavir + ribavirin therapy: Two cases report and review of literature. <i>World Journal of Clinical Cases</i> , 2019, 7, 1043-1052.	0.8	1
14	Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin. <i>Hepatology Research</i> , 2018, 48, E347-E353.	3.4	10
15	Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. <i>Journal of Gastroenterology</i> , 2018, 53, 557-565.	5.1	103
16	Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. <i>Journal of Gastroenterology</i> , 2018, 53, 566-575.	5.1	107
17	Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. <i>Hepatology</i> , 2018, 67, 505-513.	7.3	94
18	Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2018, 24, 4304-4310.	3.3	5

#	ARTICLE	IF	CITATIONS
19	A patient with type I Gaucher disease who switched from enzyme replacement therapy to substrate reduction therapy after having of CYP2D6 polymorphisms checked. <i>Acta Hepatologica Japonica</i> , 2018, 59, 243-251.	0.1	0
20	New endoscopic classification of cascade stomach, a risk factor for reflux esophagitis. <i>Journal of Gastroenterology</i> , 2017, 52, 211-217.	5.1	6
21	Clinical and virological features of acute hepatitis E in Gunma prefecture, Japan between 2004 and 2015. <i>Hepatology Research</i> , 2017, 47, 435-445.	3.4	16
22	Spontaneous remission of hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic hepatitis C. <i>Hepatology Research</i> , 2017, 47, 1346-1353.	3.4	14
23	Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients. <i>Advances in Therapy</i> , 2017, 34, 1449-1465.	2.9	14
24	Minimizing the effect of warfarin potassium during daclatasvir/asunaprevir combination therapy in a case of chronic hepatitis C after aortic dissection. <i>Acta Hepatologica Japonica</i> , 2017, 58, 22-27.	0.1	2
25	Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. <i>Hepatology</i> , 2015, 62, 1037-1046.	7.3	146
26	A case of chronic hepatitis C accompanied by marked thrombocytopenia during combination therapy with daclatasvir and asunaprevir. <i>Acta Hepatologica Japonica</i> , 2015, 56, 603-609.	0.1	2
27	Expression of amino acid transporters (<scp>LAT1</scp>, <scp>ASCT2</scp> and <scp>xCT</scp>) as clinical significance in hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, 1014-1022.	3.4	51
28	Full genome analysis of a European-type genotype 3 hepatitis E virus variant obtained from a Japanese patient with autochthonous acute hepatitis E. <i>Journal of Medical Virology</i> , 2015, 87, 1067-1071.	5.0	10
29	A Prospective Randomized Controlled Trial of AJG522 versus Standard PEG + E as Bowel Preparation for Colonoscopy. <i>BioMed Research International</i> , 2015, 2015, 1-8.	1.9	7
30	Randomized trial of interferon-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. <i>Hepatology</i> , 2015, 61, 1523-1532.	7.3	78
31	Spleen Stiffness Correlates with the Presence of Ascites but Not Esophageal Varices in Chronic Hepatitis C Patients. <i>BioMed Research International</i> , 2013, 2013, 1-7.	1.9	16
32	Frequency of null genotypes of glutathione S-transferase M1 and T1 in Japanese patients with drug-induced liver injury. <i>Hepatology Research</i> , 0, , .	3.4	1